Effect of synbiotics supplementation and anti-inflammatory-antioxidant rich diet on inflammatory marker and clinical manifestations in patients with progressive forms of Multiple Sclerosis

Esfahan University of Medical Sciences0 个研究点目标入组 70 人开始时间: 待定最近更新: 2021年8月30日

适应症

试验速览

暂无简介。

•Progressive MS Patients based on EDSS criteria (RRMS, PPMS, PRMS), who agree to participate in the study.
•Aged between 20-60 years old
•Having basic literacy
•Mental acceptance for participation and compliance

•Non-compliance with diet and supplement (adherence rate below 80 %)
•participation in other clinical trials at one time
•The occurrence of acute & serious medical conditions (urgent surgeries, accidents)
•COVID-19 infection (during the study)
•Taking immunomodulatory drugs - commons in relapsing-remitting MS- during and 6 months before the intervention (such as interferons, Sphingosine-1-phosphate receptor modulators, monoclonal antibodies, dimethyl fumarate)
•Regular consumption of anti-anxiety and anti-depressant drugs during and six months before the intervention
•Taking the other forms of synbiotic, probiotic, prebiotic, and postbiotic supplements during and 6 months before the intervention
•Taking antibiotics during and 2 months before the intervention
•Taking corticosteroids (for example methylprednisolone in doses more than 30 mg/day) and adrenocorticotropin hormone as full doses during and 6 months before the intervention
•Regular smoking (at least two cigarettes per day)
•Patients with pancreatitis, sepsis, dialysis, chronic diarrhea, and inpatient individuals with or without central venous catheter
•Patients who are waiting for abdominal surgeries
•Patients with acute immune deficiencies such as AIDS and cancers
•Patients with short bowel syndrome or at risk for mesenteric ischemia
•Patients who are in pregnancy or breastfeeding period or those with pregnancy attempt
•The unwillingness to cooperate

发起方